1 - 12 of 12

Alix E. Seif, MD, MPH

Alix E. Seif

Dr. Seif's research centers on manipulating the human innate and immune systems to treat children with acute lymphoblastic leukemia (ALL). The long-term goal of her research is to identify innate and adaptive immune mechanisms that can be used to treat pediatric ALL more effectively, and with less toxicity, than existing therapies.


Jeffrey H. Silber, MD, PhD

Jeffrey H. Silber

Dr. Silber is the director of the Center for Outcomes Research at CHOP, and is an internationally known authority on outcomes measurement and severity adjustment for both adult and pediatric applications.


Rebecca A. Simmons, MD

Rebecca A. Simmons

The principal goal of Dr. Simmons' research program is to elucidate the underlying molecular mechanisms that link an aberrant intrauterine milieu to the later development of diseases in adulthood. She has made many seminal contributions to the understanding of the role that epigenetic modifications play in developmental programming of obesity and type 2 diabetes.


Joseph W. St. Geme, III, MD

Joseph W. St. Geme

Dr. St. Geme's research focuses on bacterial pathogenesis, with an emphasis on defining the molecular and cellular determinants of Haemophilus influenzae and Kingella kingae disease.


Charles A. Stanley, MD

Charles A. Stanley Headshot

Dr. Stanley’s lab has identified many of the genes and syndromes associated with congenital hyperinsulinism including ABCC8, GCK, GLUD1, and Turner and Beckwith syndromes. Working with clinical and rodent model studies, his lab team has identified distinctive phenotypes of these disorders, including diazoxide unresponsiveness, leucine sensitivity, and protein sensitivity. Dr. Stanley continues to seek new diagnostic and treatment paradigms for infants with acquired and genetic disorders of hyperinsulinism.


Dava Szalda, MD, MSHP

Dava Szalda

Dr. Szalda's research focuses on the transition from pediatric to adult care for young adults with medical complexity and cancer survivorship.